Literature DB >> 33384663

Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead.

Annamaria Colao1, Filomena de Nigris2, Roberta Modica3, Claudio Napoli4.   

Abstract

Neuroendocrine tumors, or NETs, are cancer originating in neuroendocrine cells. They are mostly found in the gastrointestinal tract or lungs. Functional NETs are characterized by signs and symptoms caused by the oversecretion of hormones and other substances, but most NETs are non-functioning and diagnosis in advanced stages is common. Thus, novel diagnostic and therapeutic strategies are warranted. Epigenetics may contribute to refining the diagnosis, as well as to identify targeted therapy interfering with epigenetic-sensitive pathways. The goal of this review was to discuss the recent advancement in the epigenetic characterization of NETs highlighting their role in clinical findings.
Copyright © 2020 Colao, de Nigris, Modica and Napoli.

Entities:  

Keywords:  biomarkers; epigenetics; neuroendocrine; neuroendocrine neoplasms; neuroendocrine tumor; trials

Year:  2020        PMID： 33384663      PMCID： PMC7770585          DOI： 10.3389/fendo.2020.604341

Source DB:  PubMed          Journal:  Front Endocrinol (Lausanne)        ISSN： 1664-2392            Impact factor:   5.555


  108 in total

1.  MicroRNAs associated with small bowel neuroendocrine tumours and their metastases.

Authors:  Helen C Miller; Adam E Frampton; Anna Malczewska; Silvia Ottaviani; Euan A Stronach; Rashpal Flora; Daniel Kaemmerer; Gert Schwach; Roswitha Pfragner; Omar Faiz; Beata Kos-Kudła; George B Hanna; Justin Stebbing; Leandro Castellano; Andrea Frilling
Journal:  Endocr Relat Cancer       Date:  2016-06-27       Impact factor: 5.678

2.  Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status.

Authors:  L Bodei; M Kidd; I M Modlin; V Prasad; S Severi; V Ambrosini; D J Kwekkeboom; E P Krenning; R P Baum; G Paganelli; I Drozdov
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-07       Impact factor: 9.236

3.  Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice.

Authors:  Anne-Sophie Dussol; Marie-Odile Joly; Cecile Vercherat; Julien Forestier; Valérie Hervieu; Jean-Yves Scoazec; Catherine Lombard-Bohas; Thomas Walter
Journal:  Cancer       Date:  2015-06-08       Impact factor: 6.860

4.  Global microRNA profiling of pancreatic neuroendocrine neoplasias.

Authors:  Chistoph Thorns; Claudia Schurmann; Niklas Gebauer; Henri Wallaschofski; Christiane Kümpers; Veronica Bernard; Alfred C Feller; Tobias Keck; Jens K Habermann; Nehara Begum; Hendrik Lehnert; Georg Brabant
Journal:  Anticancer Res       Date:  2014-05       Impact factor: 2.480

5.  Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

Authors:  Martyn E Caplin; Marianne Pavel; Jarosław B Ćwikła; Alexandria T Phan; Markus Raderer; Eva Sedláčková; Guillaume Cadiot; Edward M Wolin; Jaume Capdevila; Lucy Wall; Guido Rindi; Alison Langley; Séverine Martinez; Joëlle Blumberg; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2014-07-17       Impact factor: 91.245

6.  PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.

Authors:  Lisa Bodei; Mark S Kidd; Aviral Singh; Wouter A van der Zwan; Stefano Severi; Ignat A Drozdov; Anna Malczewska; Richard P Baum; Dik J Kwekkeboom; Giovanni Paganelli; Eric P Krenning; Irvin M Modlin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-14       Impact factor: 9.236

7.  Epigenetic dysregulation and poorer prognosis in DAXX-deficient pancreatic neuroendocrine tumours.

Authors:  Christodoulos P Pipinikas; Harpreet Dibra; Anna Karpathakis; Andrew Feber; Marco Novelli; Dahmane Oukrif; Guiseppe Fusai; Roberto Valente; Martyn Caplin; Tim Meyer; Andrew Teschendorff; Christopher Bell; Tiffany J Morris; Paolo Salomoni; Tu-Vinh Luong; Brian Davidson; Stephan Beck; Christina Thirlwell
Journal:  Endocr Relat Cancer       Date:  2015-04-21       Impact factor: 5.678

8.  Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumors.

Authors:  Su-Chen Li; Ahmed Essaghir; Cécile Martijn; Ricardo V Lloyd; Jean-Baptiste Demoulin; Kjell Oberg; Valeria Giandomenico
Journal:  Mod Pathol       Date:  2013-01-18       Impact factor: 7.842

9.  Profiling of metastatic small intestine neuroendocrine tumors reveals characteristic miRNAs detectable in plasma.

Authors:  Michaela Bowden; Chensheng W Zhou; Sui Zhang; Lauren Brais; Ashley Rossi; Laurent Naudin; Arunthi Thiagalingam; Ewa Sicinska; Matthew H Kulke
Journal:  Oncotarget       Date:  2017-04-07

10.  Cell-Free DNA From Metastatic Pancreatic Neuroendocrine Tumor Patients Contains Tumor-Specific Mutations and Copy Number Variations.

Authors:  Gitta Boons; Timon Vandamme; Marc Peeters; Matthias Beyens; Ann Driessen; Katrien Janssens; Karen Zwaenepoel; Geert Roeyen; Guy Van Camp; Ken Op de Beeck
Journal:  Front Oncol       Date:  2018-11-01       Impact factor: 6.244
View more
  5 in total

1.  Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis.

Authors:  Viola Melone; Annamaria Salvati; Domenico Palumbo; Giorgio Giurato; Giovanni Nassa; Francesca Rizzo; Luigi Palo; Alessandro Giordano; Mariarosaria Incoronato; Mario Vitale; Caterina Mian; Immacolata Di Biase; Stefano Cristiano; Viviana Narciso; Monica Cantile; Annabella Di Mauro; Fabiana Tatangelo; Salvatore Tafuto; Roberta Modica; Claudia Pivonello; Marco Salvatore; Annamaria Colao; Alessandro Weisz; Roberta Tarallo
Journal:  J Transl Med       Date:  2022-07-06       Impact factor: 8.440

2.  Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias.

Authors:  Esther Mettler; Christian Fottner; Neda Bakhshandeh; Anja Trenkler; Robert Kuchen; Matthias M Weber
Journal:  Cancers (Basel)       Date:  2022-02-17       Impact factor: 6.639

3.  Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Luigi Barrea; Giovanna Muscogiuri; Roberta Modica; Barbara Altieri; Gabriella Pugliese; Roberto Minotta; Antongiulio Faggiano; Annamaria Colao; Silvia Savastano
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-18       Impact factor: 5.555

4.  Pancreatic Cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation.

Authors:  Maria Teresa Vietri; Giovanna D'Elia; Gemma Caliendo; Luisa Albanese; Giuseppe Signoriello; Claudio Napoli; Anna Maria Molinari
Journal:  Genes (Basel)       Date:  2022-02-09       Impact factor: 4.096

Review 5.  Circulating Neuroendocrine Tumor Biomarkers: Past, Present and Future.

Authors:  Paweł Komarnicki; Jan Musiałkiewicz; Alicja Stańska; Adam Maciejewski; Paweł Gut; George Mastorakos; Marek Ruchała
Journal:  J Clin Med       Date:  2022-09-21       Impact factor: 4.964
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.